Effect of Behavioral Weight Management Interventions on Symptoms of Binge-Eating Disorder and Bulimia Nervosa: A Systematic Review and Meta-Analysis.

Obes RevMay 21, 2026 (epub)
Clinical ResearchPsychiatry

Michael P Berry, Craig G Gunderson, Samer Ein Alshaeba et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed behavioral weight management interventions and eating-disorder symptoms in people diagnosed with binge-eating disorder (BED) or bulimia nervosa (BN). It included 22 experimental groups from 11 trials, with 890 participants. Symptoms decreased on average from baseline after intervention in all trials. Compared with control groups, interventions showed no significant difference in posttreatment change in binge-eating frequency (MD = 0.59, 95% CI [-0.86, 1.86]), global symptom severity, or pooled symptom outcomes. Results varied according to control-group and intervention type.

Key findings

  • Across all trials, eating-disorder symptoms decreased on average from baseline after weight management interventions.
  • There was no significant between-group difference in binge-eating frequency change: MD = 0.59, 95% CI [-0.86, 1.86].
  • Between-group differences were not significant for global symptom severity (MD = 0.03, 95% CI [-0.15, 0.21]) or pooled outcomes (g = 0.04, 95% CI [-0.20, 0.29]).
  • Symptom decreases were greater versus no-treatment than active controls, and outcomes differed by intervention type.

Why it matters

Intentional weight loss has been considered a potential concern for people with BED or BN because it might worsen eating-disorder symptoms. These pooled findings do not show greater posttreatment symptom worsening with behavioral weight management than with comparison conditions, and suggest such interventions may be a treatment option. The evidence remains preliminary and does not establish long-term effects.

What to keep in mind

The review included a small number of trials, with heterogeneity in study designs and outcome measures and sparse long-term outcome data.

Source

Published in Obes Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.